Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bright Minds Biosciences Inc. (DRUG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer under Commission File No. 001-40997. Bright Minds files reports on Form 6-K to furnish material information to U.S. investors, including clinical updates, financing transactions, interim financial statements and other significant developments related to its biotechnology business focused on neurological and psychiatric disorders.
Among the filings, investors can find Form 6-K reports describing public offerings of common shares made under shelf registration statements on Form F-3. A January 8, 2026 Form 6-K outlines an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. for an underwritten public offering of 1,945,000 common shares. The filing details gross proceeds, the underwriters’ option to purchase additional shares, and the company’s stated intention to use net proceeds to fund clinical trials in absence seizures, DEE and Prader-Willi Syndrome, initiate Phase 1 trials for BMB-105, support earlier-stage research and development, and for general corporate and working capital purposes.
Other 6-K submissions incorporate news releases by reference, such as announcements on the initiation of the Prader-Willi Syndrome program, expansion of the scientific advisory board, and positive Phase 2 data for BMB-101. Bright Minds also uses Form 6-K to file condensed interim consolidated financial statements, management’s discussion and analysis, and related CEO and CFO certifications, which are incorporated by reference into its Form F-3 registration statements.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain the key points of lengthy documents, including shelf registrations, underwriting agreements and clinical disclosures. Users can quickly identify how new filings affect Bright Minds’ capital structure, clinical plans and risk profile, and can review exhibits such as legal opinions and consent letters that accompany major financing transactions.
Bright Minds Biosciences Inc. has filed a preliminary prospectus supplement for a $100,000,000 public offering of common shares and, for certain large investors, pre-funded warrants to buy common shares. The pre-funded warrants are sold at the share price minus $0.001 and carry a token exercise price of $0.001 per share, are exercisable at any time, and include 4.99% or 9.99% ownership caps to limit post‑offering beneficial ownership.
The company has also granted underwriters a 30‑day option to purchase additional common shares. Net proceeds are expected to fund future clinical trials in absence epilepsy, developmental and epileptic encephalopathies, Prader‑Willi Syndrome, initiation of phase 1 trials for BMB‑105, earlier-stage research programs, and general corporate purposes. Bright Minds had 7,787,161 common shares outstanding as of the prospectus supplement date, with additional shares reserved under options, RSUs and warrants, so this financing may significantly dilute existing holders and increase share count over time.
Bright Minds Biosciences reported positive topline Phase 2 results from its BREAKTHROUGH trial of BMB-101 in adults with drug‑resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label study enrolled 24 patients and met its primary efficacy endpoints in both cohorts, showing robust seizure reductions with a favorable safety profile.
In the Absence cohort (n=11 efficacy‑evaluable), BMB‑101 achieved a 73.1% median reduction in absence seizures lasting at least 3 seconds and a 74.4% median reduction in total seizure time, with p = 0.012. In the DEE cohort (n=6), there was a 63.3% median reduction in major motor seizures, including Lennox‑Gastaut, Dravet, and Rett patients.
BMB‑101 was generally well tolerated, with most adverse events mild or moderate and no treatment‑related serious events. Patients with Absence Seizures also showed a 90% increase in REM sleep without increasing total sleep time. Based on these findings, Bright Minds has begun preparations for global registrational trials in Absence Seizures and DEE and plans to start a Prader‑Willi syndrome study in Q1 2026.
Bright Minds Biosciences Inc. filed a Form 6-K as a foreign private issuer for November 2025. The filing furnishes a news release dated November 17, 2025 as Exhibit 99.1. That news release is incorporated by reference into the company’s two existing Form F-3 shelf registration statements.
Bright Minds Biosciences Inc. filed an amended Form 6-K to update a prior submission for November 2025. The amendment mainly clarifies that Exhibit 99.1, a news release dated November 6, 2025, is incorporated by reference into two existing Form F-3 shelf registration statements.
Janus Henderson Group plc and its affiliated Janus Henderson Biotech Innovation Master Fund Ltd report substantial beneficial holdings in Bright Minds Biosciences Inc. The parent reporting person discloses ownership of 1,145,660 shares representing 16.3% of the outstanding common stock, while the fund reports 984,485 shares or 14.0%. Both reporting persons indicate shared voting and dispositive power for their respective holdings and 0 shares of sole voting or dispositive power.
The filing identifies the reporting entities as institutional investors (designations include IA, HC for the parent and IV for the fund), notes that certain subsidiaries act as registered investment advisers, and includes a power-of-attorney authorizing compliance filings.
Bright Minds Biosciences' Schedule 13G/A shows Sio Capital Management, LLC beneficially owns 512,338 common shares, representing 7.27% of the outstanding class based on 7,043,989 shares disclosed by the issuer. Sio reports shared voting and shared dispositive power and no sole voting or dispositive power. Sio is a Delaware registered investment adviser to affiliated funds that directly hold the reported shares. A footnote states Sio GP, LLC and Michael Castor may be deemed to have influence, though that beneficial ownership is expressly disclaimed. The filer certifies the holdings are held in the ordinary course of business and not to change control.
Bright Minds Biosciences Inc. filed a Form 6-K attaching its Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 and its Management's Discussion and Analysis for the second quarter ended March 31, 2025. The filing lists Exhibits 99.1–99.4, including CEO and CFO certifications, and states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694). The report is signed by CFO Ryan Cheung and dated August 8, 2025.